SCHEMBL2920702

SCHEMBL2920702

CCOC(=O)Nc1cc(Nc2ncc3ccc(F)c(C)c3n2)cc2[nH]cnc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 2/20 0.38
CDK1 P06493 2/20 0.37
KIT P10721 1/20 0.37
TNIK Q9UKE5 1/20 0.36
P2RX3 P56373 1/20 0.35
KCNQ3 O43525 1/20 0.35
KCNQ2 O43526 1/20 0.35
KCNQ4 P56696 1/20 0.35
KCNQ5 Q9NR82 1/20 0.35
SYK P43405 3/20 0.35
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
USP2 O75604 1/20 0.33
EGFR P00533 2/20 0.33
KDR P35968 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CDK9 P50750 1/20 0.33
CCNA1 P78396 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13175537 0.90 KIT (0.39) CDK1KITTNIKSYKCYP1A2
SCHEMBL2916349 0.86 TNIK (0.43) CDK1KITTNIKSYKEGFR
SCHEMBL2918651 0.85 KIT (0.38) KITKCNQ3KCNQ2KCNQ4KCNQ5
SCHEMBL2912579 0.82 ALDH1A1 (0.38) BRAFKITP2RX3KCNQ3KCNQ2
SCHEMBL2918740 0.78 CDK1 (0.42) CDK1TNIKSYKCDK2CDK9
SCHEMBL2913576 0.74 EGFR (0.40) KITEGFRKDRNPC1MAPT
SCHEMBL2919023 0.73 KIT (0.40) KITTNIKSYKEGFRKDR
SCHEMBL2919324 0.73 ALDH1A1 (0.40) KITTNIKSYKEGFRKDR
SCHEMBL2921547 0.71 KIT (0.41) KITSYKKDRNPC1
SCHEMBL2912617 0.70 CYP1A2 (0.43) KCNQ3KCNQ2KCNQ4KCNQ5CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K BRAF 173/4885CDK1 98/4885KIT 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.